Biomarkers of disease activity in multiple sclerosis

Journal of the Neurological Sciences

Volumn 305, Issue 1-2, 2011, Pages 1-10

  Graber, Jerome J ^a   Dhib Jalbut, Suhayl ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Cytokine; Disease activity; Glatiramer; Interferon; Interleukin; Multiple sclerosis; T cell

Indexed keywords

AQUAPORIN 4; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT FACTOR H; CUTANEOUS T CELL ATTRACTING CHEMOKINE; GAMMA INTERFERON; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NERVE CELL ADHESION MOLECULE; NEUTROPHIL COLLAGENASE; OSTEOPONTIN; PROGRAMMED DEATH 1 LIGAND 1; RANTES; RECOMBINANT BETA INTERFERON; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

B LYMPHOCYTE; CEREBROSPINAL FLUID; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; IMMUNOPATHOGENESIS; MACROPHAGE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; RELAPSE; REVIEW; T LYMPHOCYTE; TISSUE INJURY; TISSUE REPAIR;

BIOMARKERS, PHARMACOLOGICAL; GENETIC MARKERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS;

EID: 79955678019     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.03.026     Document Type: Review

References (144)

1. Graber JJ, McGraw CA, Kimbrough D, Dhib-Jalbut S. Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg 2010;112:583-91.
2. Stoop MP, Singh V, Dekker LJ, Titulaer MK, Stingl C, Burgers PC, et al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS ONE 2010;5:e12442.
3. Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 2010;31:770-88.
4. Krakauer M, Sorensen PS, Khademi M, Olsson T, Sellebjerg F. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol 2006;64:155-63. (Pubitemid 44034320)
5. Sega S, Wraber B, Mesec A, Horvat A, Ihan A. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 2004;106:255-8. (Pubitemid 38716157)
6. Graber JJ, Zhan M, Ford D, Kursch F, Francis G, Panitch H, et al. Interferon-beta induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. J Neuroimmunol 2005;161:169-76. (Pubitemid 40340885)
7. Graber JJ, Ford D, Zhan M, Francis G, Panitch H, Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 2007;185:168-74. (Pubitemid 46497443)
8. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007;68:S13-21.
9. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in neurologic disease. Pharmacol Ther 2009;121:147-59.
10. De Jager PL, Rossin E, Pyne S. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8 low cells. Brain 2008;131:1701-11. (Pubitemid 351957464)
11. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-5.
12. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger exacerbations? Acta Neurol Scand 1988;78:318-23.
13. Becher B, Giacomini PS, Pelletier D, McCrea P, Prat A, Antel J. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann Neurol 1999;45:247-50. (Pubitemid 29072372)
14. Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler 2007;13:754-62. (Pubitemid 47074099)
15. Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, Khoury SJ. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102:671-8. (Pubitemid 28399598)
16. Fassbender K, Ragoschke A, Rossol S, Schwartz A, Mielke O, Paulig A, et al. Increased release of interleukin 12p40 in MS: association with cerebral inflammation. Neurology 1998;51:753-8. (Pubitemid 28449255)
17. Makhlouf K, Weiner H, Khoury S. Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J Neuroimmunol 2001;119:145-9. (Pubitemid 32781740)
18. Van Boxel-Dezaire A, Hoff S, Van Oosten B, Verweij CL, Drager AM, Ader HJ, et al. Decreased interleukin-10 and increase IL-12p40 mRNA are associated with disease activity and characterize different stages in multiple sclerosis. Ann Neurol 1999;45:695-703. (Pubitemid 29260746)
19. Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, et al. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010;16:801-9.
20. Losy J, Michalowska-Wender G, Wender M. Interleukin 12 and interleukin 10 are affected differentially by treatment of multiple sclerosis with glatiramer acetate (Copaxone). Folia Neuropathol 2002;40:173-5. (Pubitemid 36167950)
21. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-22.
22. Van Boxel-Dezaire A, van Trigt-Hoff S, Killestein J, Schrijver HM, van Houwelingen JC, Polman CH, et al. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: does baseline interleukin 12p35 messenger RNA predict the efficacy of treatment? Ann Neurol 2000;48:313-22.
23. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4. (Pubitemid 29186827)
24. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499-509.
25. Graber JJ, Allie SR, Mullen K, Jones MV, Wang T, Krishnan C, et al. Interleukin-17 in multiple sclerosis and transverse myelitis. J Neuroimmunol 2008;196(1-2):124-32.
26. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, et al. T helper type I and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-13.
27. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, et al. Repeated subcutaneous infections of IL-12/23 p40 neutralizing antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled randomized, dose-ranging study. Lancet Neurol 2008;7:796-804.
28. Waubant E, Gee L, Bacchetti P, Sloan R, Cotleur A, Rudick R, et al. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing remitting MS. J Neuroimmunol 2001;112:139-45.
29. Petereit H, Pukrop R, Fazekas F, Bamborschke SU, Ropele S, Kolmel HW, et al. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. J Neurol Sci 2003;206:209-14. (Pubitemid 36143730)
30. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune deviation. J Neuroimmunol 1998;92:113-21. (Pubitemid 29015996)
31. Rudick RA, Ransahoff RM, Lee JC, Peppler R, Yu M, Mathisen PM, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998;50:1294-300.
32. Bartosik-Psujek H, Stelmasiak Z. Interleukin-10 levels as potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin Neurol Neurosurg 2006;108:644-7. (Pubitemid 44415291)
33. Ahn J, Feng X, Patel N, Dhawan N, Reder AT. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci 2004;9:1547-55. (Pubitemid 38918613)
34. Gilli F, Valentino P, Caldano M, Granieri L, Capobianco M, Malucchi S, et al. Expression and regulation of IFN-alpha/beta receptor in IFN-beta-treated patients with multiple sclerosis. Neurology 2008;71:1940-7.
35. Correale J, Villa A. Role of CD8+CD25+FoxP3+ regulatory T cells in multiple sclerosis. Ann Neurol 2010;67:625-38.
36. Anderson D, Sharpe A, Hafler D. The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr Opin Immunol 1999;11:677-83.
37. Gene K, Dona D, Reder A. Increased C80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997;99:2664-71. (Pubitemid 27259813)
38. Boylan M, Crockard A, McDonnell G, Armstrong M, Hawkins S. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone. J Neurol Sci 1999;167:79-89. (Pubitemid 29393094)
39. Wiesemann E, Deb M, Trebst C, Hemmer B, Stangel M, Windhagen A. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis. Mult Scler 2008;14:166-76.
40. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PDL-1 in patients with different patterns of disease. J Immunol 2009;183:4984-93.
41. Lopatinskaya L, Zwemmer J, Uitdehaag B, Lucas K, Polman C, Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult Scler 2006;12:704-9. (Pubitemid 46111762)
42. Lopatinskaya L, Van Boxel-Dezaire AH, Barkhof F, Polman CH, Lucas CJ, Nagelkerken L. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. J Neuroimmunol 2003;128:123-31. (Pubitemid 36566426)
43. Sharief M, Noori M, Douglas M, Noori M. Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol 2002;9:503-10. (Pubitemid 35013876)
44. Sharief M, Semra Y. Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis. Eur J Neurol 2002;59:1115-21. (Pubitemid 34755824)
45. Bittner S, Bobak N, Herrmann AM, Gobel K, Meuth P, Hohn KG, et al. Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann Neurol 2010;68:58-69.
46. Cree B. Neuromyelitis optica: diagnosis, pathogenesis and treatment. Curr Neurol Neurosci Rep 2008;8:427-33.
47. Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin and diagnostic relevance. J Neuroinflammation 2010;7:52.
48. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFN-β-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010;75:1423-7.
49. Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon-beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010;17:672-6.
50. Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N, et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before disease onset. Neurology 2009;72:1960-1.
51. Klawiter EC, Alvarez E, Xu J, Paciorkowski AR, Zhu L, Parks BJ, et al. NMO-IgG detected in CSF in seronegative NMO. Neurology 2009;72:1101-3.
52. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B, et al. Recommendations for clinical use data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740-50.
53. Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008;275:7-17.
54. Karussis D, Tietelbaum D, Sicsic C, Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010;220:125-30.
55. Kuenz B, Lutterotti A, Ehling R, Gneiss C, Haemmerle M, Rainer C, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 2008;3:e2559.
56. Tomassini V, De Giglio L, Reindl M, Russo P, Pestalozza I, Pantano P, et al. Antimyelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007:1086-94. (Pubitemid 351541411)
57. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007;356:371-8. (Pubitemid 46148779)
58. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-45. (Pubitemid 36818783)
59. Menge T, Lalive PH, von Budingen HC, Cree B, Hauser SL, Genain CP. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol 2005;116:453-9. (Pubitemid 41096558)
60. Farrell RA, Antony D, Wall GR, Clark DA, Fisniku L, Swanton J, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009;73:32-8.
61. Ingram G, Bugert JJ, Loveless S, Robertson NP. Anti-EBNA-IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol 2010;17:1386-9.
62. Quintana FJ, Farez MG, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008;105:18889-94.
63. Jensen MA, Yanowitch RN, Reder AT, White DM, Arnason BG. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler 2010 Jan;16:30-8.
64. Pinter C, Beltrami S, Caputo D, Ferrante P, Clivio A. Presence of autoantibodies against complement regulatory proteins in relapsing-remitting multiple sclerosis. J Neurovirol 2000;6(S2):S42-6.
65. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, et al. Complement regulatory factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010;133:1602-11.
66. Sawai S, Umemura H, Mori M, Satoh M, Hayakawa S, Kodera Y, et al. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis. J Neuroimmunol 2010;218:112-5.
67. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-6.
68. Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol 2003;145:103-14.
69. Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56bright NK cells. J Immunol 2010;185:1311-20.
70. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72.
71. Maimone D, Gregory S, Arnason BG, Reder AT. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 1991;32:67-74.
72. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
73. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8. (Pubitemid 33096700)
74. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004;155:155-60. (Pubitemid 39165788)
75. Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009;132:3342-52.
76. Soilu-Hanninen M, Laaksonen M, Hanninen A, Eralinna JP, Panelius M. Down-regulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in multiple sclerosis. J Neuroimmunol 2005;167:175-82. (Pubitemid 41242299)
77. Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, Ader HJ, Barkhof F, et al. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. J Neuroimmunol 2005;158:222-30. (Pubitemid 39626090)
78. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelz M, et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 2010;227:190-4.
79. Waubant E, Goodkin D, Gee L, Bacchetti P, Sloan R, Stewart T, et al. Serum MMP-9 and TIMP-1 levels are related to MRi activity in relapsing multiple sclerosis. Neurology 1999;53:1397-401. (Pubitemid 29491927)
80. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, et al. IFN-beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesion in patients with SPMS. Neurology 2003;60:52-7. (Pubitemid 36070643)
81. Trojano M, Avolio C, Liuzzi G, Ruggieri M, Defazio G, Liguori M, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFN-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-8. (Pubitemid 29491928)
82. Franciotta D, Martino G, Zardini E, Zardini E, Furlan R, Bergamaschi R, et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001;115:192-8. (Pubitemid 32245668)
83. Putheti P, Morris M, Stawiarz L, Teleshova N, Kivisakk P, Pashenkov M, et al. Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables. Eur J Neurol 2003;10:529-35. (Pubitemid 38021468)
84. Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of disease. Eur J Neurol 2005;12:49-54.
85. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen P, et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 2009;16:1291-8.
86. Neuteboom RF, Verbraak E, Voerman JS, van Meurs M, Steegers EA, de Groot CJ, et al. First trimester interleukin 8 levels are associated with postpartum relapse in multiple sclerosis. Mult Scler 2009;15:1356-8.
87. Mahad DJ, Lawrey J, Howell SJ, Woodruffe MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult Scler 2003;9:189-98. (Pubitemid 36426993)
88. Fox RJ, Kivisakk P, Fisher E, Tucky B, Lee JC, Rudick RA, et al. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult Scler 2008;14:1036-43.
89. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler 2009;15:1271-9.
90. Sellebjerg F, Kristiansen TB, Wittenhagen P, Garred P, Eugen-Olsen J, Fredriksen JL, et al. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 2007;115:413-8. (Pubitemid 46776327)
91. Infante-Duarte C, Weber A, Kratzschmar J, Prozorovski T, Pikol S, Hamann I, et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J 2005;19:1902-4. (Pubitemid 41598789)
92. Van Veen T, Nielsen J, Berkhof J, Barkhof F, Kamphorst W, Bo L, et al. CCL5 and CCR5 genotypes modify clinica, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2008;190:157-64. (Pubitemid 47625612)
93. Van der Voort LF, Vennegoor A, Visser A, Knol D, Uitdehaag M, Barkhof F, et al. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology 2010;75:1228-33.
94. Hesse D, Sellebjerg F, Sorensen P. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009;73:372-7.
95. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008;70:1119-27. (Pubitemid 351464769)
96. Simpson S, Taylor B, Blizzard L, Ponsonby AL, Pittas F, Tremlett H, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68:193-203.
97. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003;215:37-44. (Pubitemid 37279143)
98. Lalive PH, Kantengwa S, Benhoucha M, Juillard C, Chofflon M. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients. J Neuroimmunol 2008;197:147-51.
99. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Scancricca C, et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005;62:176-82. (Pubitemid 41176501)
100. Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D, et al. Uric acid levels in sera from patients with multiple sclerosis. J Neurol 2001;248:121-6. (Pubitemid 32245422)
101. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, et al. Serum uric acid and multiple sclerosis. Neurol Sci 2002;23:183-8. (Pubitemid 35345492)
102. Sternberg Z, Hennies C, Sternberg D, Bistulfi GL, Kazim L, Benedict RH, et al. Plasma pentosidine: a potential biomarker in the management of multiple sclerosis. Mult Scler 2011;17(2):157-63.
103. Rejdak K, Leary SM, Petzold A, Thompson AJ, Miller DH, Giovannoni G. Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis. Mult Scler 2010;16:1066-72.
104. Habek M, Borovecki F, Brinar VV. Genomics in multiple sclerosis. Clin Neurol Neurosurg 2010;112:621-4.
105. Link H, Huang Y-M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006;180:17-28. (Pubitemid 44692326)
106. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis: cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008;255:1023-31.
107. Calais G, Forzy G, Crinquette C, Mackowiak A, de Seze J, Blanc F, et al. Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler 2010;16:87-92.
108. Rudick RA, Medendorp SV, Namey M, Boyle S, Fischer J. Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler 1995;1:150-5.
109. Rinker JR, Trinkaus K, Cross AH. Elevated CSF free kappa lights chains correlate with disability prognosis in multiple sclerosis. Neurology 2006;67:1288-90. (Pubitemid 44563847)
110. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006;12:138-43. (Pubitemid 43050089)
111. Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63:611-20.
112. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-104. (Pubitemid 47355604)
113. Malmestrom C, Andersson BA, Haghighi S, Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS. J Neuroimmunol 2006;175:176-82.
114. Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch Neurol 2008;65:232-5. (Pubitemid 351240786)
115. Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16:1443-52.
116. Kraus J, Oschmann P, Engelhardt B, Stolz E, Kuehne BS, Laske C, et al. CD45RA+ ICAM-3+ lymphocytes in cerebrospinal fluid and blood as markers of disease activity in patients with multiple sclerosis. Acta Neurol Scand 2000;102:326-32.
117. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-33. (Pubitemid 27114043)
118. Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, et al. Chemokines inmultiple sclerosis: CXCL12 and CXL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129:200-11. (Pubitemid 43063771)
119. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009;73:2003-10.
120. Szczucinksi A, Losy J. CCL5, CXCL10 and CXCL11 chemokines in patientswith active and stable relapsing-remitting multiple sclerosis. Neuroimmunomodulation 2011;18:67-72.
121. Sellebjerg F, Giovannoni G, Hand A, Madsen HO, Jensen CV, Garred P. Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis. J Neuroimmunol 2002;125:198-203. (Pubitemid 34327470)
122. Rejdak K, Eikelenboom MK, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004;63:1439-45. (Pubitemid 39426278)
123. Comabella M, Fernandez M, Martin R, Rivera-Vallve S, Borras E, Chiva C, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133:1082-93.
124. Massaro AR. Are there indicators of remyelination in blood or CSF of multiple sclerosis patients. Mult Scler 1998;4:228-31. (Pubitemid 28410056)
125. Lamers KJ, van Engelen BG, Gabreels FJ, Hommes OR, Borm GF, Wevers RA. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995;92:247-51.
126. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720-5. (Pubitemid 38020818)
127. Lycke JN, Karlsson JE, Anderson O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-4. (Pubitemid 28159853)
128. Brettschneider J, Maier M, Arda S, Claus A, Sussmuth SD, Kassubek J, et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Mult Scler 2005;11:261-5. (Pubitemid 40775179)
129. Salzer J, Svenningsson A, Sundstrom A. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-92.
130. Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeon CH, Polman CH, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: a three year longitudinal study. J Neurol Neurosurg Psychiatry 2005;76:206-11. (Pubitemid 40143709)
131. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41. (Pubitemid 40023234)
132. Barkhof F, Frequin ST, Hommes OR, Lamers K, Scheltens P, van Geel WJ, et al. A correlative triad of gadolinium-DTPAMRI, EDSS, and CSF-MBP in relapsingmultiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-7.
133. Lamers KJ, de Reus HP, Jongen PJ. Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis. Mult Scler 1998;4:124-6. (Pubitemid 28410036)
134. Harris VK, Diamanduros A, Good P, Zakin E, Chalivendra V, Sadiq SA. Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis 2010;40:331-9.
135. Jurewicz A, Matysiak M, Raine CS, Selmaj K. Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis. Neurology 2007;68:283-7. (Pubitemid 46148340)
136. Lindsey JW, Crawford MP, Hatfield LM. Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis. Neurology 2008;71:35-7.
137. Summers M, Swanton J, Fernando K, Dalton C, Miller MH, Cipolotti L, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008;79:955-8.
138. Furlan R, Rovaris M, Martinelli-Boneschi F, Khademi M, Bergami A, Gironi M, et al. Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol 2005;165:192-200. (Pubitemid 40984638)
139. Baranzini SE, Mousavi P, Rio J, Caillier SJ, StillmanA, Villoslada P, et al. Transcription-based prediction of response to IFNβ using supervised computational methods. PLoS Biol 2005;3:0166-76.
140. Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J, et al. Interferon-β-1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients, independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res 2008;28:317-31. (Pubitemid 351725305)
141. Wiesemann E, Deb M, Trebst C, Hemmer B, Radeke HH, Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008;128:306-13.
142. Vandenbroeck K, Comabella M. Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis. J Interferon Cytokine Res 2010;30:727-32.
143. Frisullo G, Mirabella M, Angelucci F, Caggiula M, Morosetti R, Sancricca C, et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. J Neuroimmunol 2007;192:174-83. (Pubitemid 350214563)
144. Icoz S, Tuzun E, Kurtuncu M, Durmus H, Mutlu M, Eraksoy M, et al. Enhanced IL-6 production in antiaquaporin-4antibody positive neuromyelitisoptica. Int JNeurosci 2010;120:71-5.